Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial.

Target Oncol · 2023 · PMC10191908 · PMID 37103658

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Notable CBF changes that did not reach statistical significance included enzalutamide versus darolutamide in the left dorsolateral prefrontal cortex (− 2.9%) and enzalutamide versus placebo in the right dorsolateral prefrontal cortex (− 3.4%).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.